Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies
Abstract
The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug-resistant tuberculosis (TB) containing a bedaquiline-pretomanid-based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by combining safety data from clinical trials, implementation and pharmacovigilance studies. We conducted a search using PubMed, Medline and Web of Science to identify studies that reported AE data for bedaquiline-pretomanid-based regimens. In total, 14 studies from various countries were included in the analysis, comprising seven clinical trials, six implementation studies and one pharmacovigilance study. AE detection methods differed between clinical trials and implementation studies. Clinical trials utilised structured and standardised detection methods, whereas implementation and pharmacovigilance studies relied on spontaneous reporting with a higher prevalence of AEs reported in clinical trials (62.2-100%) compared to implementation studies (41.8-72.8%). Serious AEs developed in 2.2-30.2% of patients. Among those with serious AEs, 7.7-54.3% required interruption of TB drugs, while 3.5-13% required withdrawal of TB drugs. AE outcomes showed full recovery in 79.2%. However, 23-32% of patients reported AEs even after completing their treatment. Understanding AEs is crucial for healthcare professionals to enhance patient care, as early detection…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.